Cells thrive not as isolated units but as dynamic entities that constantly exchange biomolecules and organelles with their neighbors. These exchanges shape tissue development, stress responses, and repair mechanisms. For example, in certain cancers, tumor cells hijack mitochondria from surrounding cells, sustaining their metabolic demands and growth. Similar intercellular exchanges are deeply implicated in aging. However, despite the advent of cutting-edge gene editing like CRISPR and various molecular targeting tools, reliably manipulating the cytoplasmic composition of living cells has remained an unprecedented challenge. Current approaches either destroy cells outright during cytoplasm extraction or fail to deliver sizeable biomolecular cargo efficiently.

Prior methods have faced insurmountable obstacles at multiple stages. Traditional extraction approaches rely on chemical lysis, employing detergents or enzymatic digestion, which sacrificially dismantle cellular integrity. Physically disruptive methods, like ultrasound or microfluidic shear, demand fine-tuning lest vital biomolecules be damaged or cells irreparably harmed. On the delivery front, lipid nanoparticles excel only at transferring small molecules; viral vectors are constrained by cargo size, immunogenicity, and high costs; and microinjections, while precise, are technically demanding and impractical for high-throughput applications. No existing method combined the precise control, efficiency, and cell preservation necessary for live cytoplasmic content transfer—until now.

The newly developed platform utilizes a meticulously engineered thin gold membrane studded with vertically aligned nanotubes integrated on a glass tube structure. Each nanotube acts as a microscopic conduit capable of piercing the phospholipid bilayers of intact, living cells gently and precisely. This physical penetration sidesteps the destructive pitfalls of conventional extraction. By regulating the internal air pressure of the glass tube, the system can effectively “aspirate” cytoplasmic contents from donor cells, temporarily hold them within the nanotube network, then release these contents into recipient cells upon repositioning. This process occurs with microliter precision, preserving the physiological environment and cell viability.

Extensive optimization revealed that the diameter and density of the nanotubes, combined with finely tuned applied pressures, were crucial to achieving minimal cellular damage while maximizing transfer efficiency. Trials employing fluorescent markers and quantitative protein assays validated the pressure-dependent transfer of cytoplasmic constituents. Remarkably, under ideal conditions, recipient cell viability consistently stayed near a remarkable 95%, while the transfer efficiency of cytoplasmic material exceeded 90%. These performance metrics set a new standard for cytoplasmic engineering and underscore the platform’s biocompatibility and precision.

One of the most striking demonstrations of the platform’s potential was its ability to transfer intact mitochondria—functional organelles essential for cellular energy metabolism. Employing fluorescent tagging and state-of-the-art confocal microscopy, the researchers observed numerous mitochondria successfully migrating into recipient cells. More importantly, these transferred mitochondria retained functional integrity, as reflected by significantly elevated intracellular ATP levels in recipient cells relative to controls. This functional enhancement signals revolutionary prospects for mitochondrial repair therapies where dysfunctional mitochondria contribute to diseases or cellular aging.

“This technology introduces a paradigm shift in biomedical engineering,” Professor Miyake reflects. “Rather than altering the genome, we reconstruct the intracellular cytoplasmic environment to modulate cell function directly. It opens unprecedented opportunities to manipulate cell physiology without the ethical and regulatory complexities often associated with genetic modifications.” By harnessing nanomaterial design and fluidic control, the platform bridges formidable gaps between molecular precision and practical application.

The implications of this technology resonate widely. In regenerative medicine, where cell transplantation and therapy efficacy often falter due to metabolic decline and functional heterogeneity in cultured cells, this cytoplasmic injector may restore or augment the energetic capacity by directly supplementing or replacing key organelles such as mitochondria. Moreover, this capability enhances cell quality before therapeutic use, improving clinical outcomes while avoiding genome editing’s potential risks.

Beyond therapy, the platform promises advances in disease modeling and drug discovery. By enabling precise cytoplasmic swapping, researchers can create more physiologically relevant models of cellular dysfunction or pathology, investigating complex cellular responses with unparalleled fidelity. Drug screening platforms can also benefit from enhanced robustness and uniformity in cellular responses when their cytoplasmic environments are carefully engineered.

The innovative integration of nanotechnology and fluid physics encapsulated in this gold nanotube membrane injector not only overcomes long-standing technical hurdles but also positions itself as a versatile tool for future bioengineering research. It achieves a delicate balance between invasiveness and effectiveness, merging the microscopic precision of nanomaterials with the macroscopic practicality needed for widespread adoption.

In summary, the Waseda University team has propelled cell engineering into a new frontier. Their nanotube membrane-based injector offers a scalable, reproducible, and cytocompatible strategy for reshaping intracellular composition directly. The technology’s ability to enhance mitochondrial function further elevates its translational potential, signaling a fresh era in cellular manipulation with far-reaching implications across biomedicine, from fundamental research methodologies to transformative therapeutic interventions.

With this breakthrough, the scientific community gains a powerful instrument to interrogate and influence life’s most fundamental unit: the cell itself. As researchers worldwide embrace this platform, accelerated discoveries and innovative therapies may soon emerge, reaffirming the ever-expanding frontiers of science and human health.

Subject of Research: Cells

Article Title: A Nanotube Injector for Cytoplasmic Transfer and Enhanced Mitochondrial Function

News Publication Date: 17-Mar-2026

Web References: https://onlinelibrary.wiley.com/doi/10.1002/smsc.202500598

References: Bingfu Liu, Zhuhang Dai, Bowen Zhang, Kazuhiro Oyama, Chenxi Li, Yukun Chen, Mingyin Cui, and Takeo Miyake. “A Nanotube Injector for Cytoplasmic Transfer and Enhanced Mitochondrial Function,” Small Science, 17 March 2026.

Image Credits: Professor Takeo Miyake, Waseda University

Keywords: Cell biology, Molecular biology, Biochemistry, Regenerative medicine, Biomedical engineering, Nanotechnology, Materials science, Cancer, Basic research, Organelles, Cytoplasmic proteins, Mitochondria

Mitochondria are crucial intracellular structures responsible for generating adenosine triphosphate (ATP), the primary energy currency in biological systems. The ability of skin cancer cells to shuttle mitochondria into fibroblasts is facilitated by microscopic, membrane-bound tubes that form physical conduits between the cells. These nanoscopic tubes bear a striking functional resemblance to pneumatic tube systems once used to transport physical objects between locations. Such direct mitochondrial transfer represents a fascinating example of intercellular communication hijacked by malignant cells to manipulate their environment favorably.

Upon receiving mitochondria from cancer cells, the fibroblasts undergo a remarkable functional transformation into what are termed tumor-associated fibroblasts (TAFs). These reprogrammed fibroblasts demonstrate increased proliferation rates and enhanced production of ATP, thereby amplifying the metabolic support they provide to the tumor. Moreover, TAFs secrete an elevated level of growth factors and cytokines—signaling molecules that orchestrate cellular activities—fostering a microenvironment conducive to aggressive tumor expansion and invasiveness.

Beyond metabolic and proliferative changes, these hijacked fibroblasts also profoundly alter the extracellular matrix (ECM), the intricate network of proteins and glycoproteins that provide structural support to tissues. By modulating ECM composition, these tumor-associated fibroblasts create a mechanical and biochemical niche that promotes cancer cell survival, invasion, and intercellular communication. This remodeling of the ECM underlines the multifaceted role of fibroblasts not only in tissue homeostasis but also in the dynamic progression of malignancies.

The serendipitous nature of this discovery came to light when postdoctoral researcher Michael Cangkrama observed slender tube-like structures bridging cancer cells and fibroblasts in controlled co-culture environments. These nano-bridges served as channels for mitochondrial passage, a phenomenon previously unexplored in the context of cancer-to-stroma interaction. While mitochondrial transfer between cells has been documented in other physiological contexts—such as neuronal rescue following ischemic stroke—this finding marks a paradigm shift by demonstrating how cancer cells exploit a natural intercellular salvage pathway to their advantage.

Notably, while it has been recognized that stromal cells can transfer mitochondria to tumor cells enhancing tumor fitness, the demonstration of mitochondria transfer in the reverse direction—from cancer cells to fibroblasts—is unprecedented. This bi-directional exchange elucidates a complex crosstalk within the tumor microenvironment, whereby cellular communication and organelle trafficking synergize to bolster tumor growth and resilience.

Further studies at ETH Zurich established that this mitochondrial transfer phenomenon is not exclusive to skin cancer. Evidence now indicates its presence in other malignancies characterized by dense stromal components, such as breast and pancreatic cancers. The latter is especially significant given the notoriously fibrotic nature of pancreatic tumors, where abundant fibroblasts heavily influence disease progression and therapy resistance.

Deciphering the molecular underpinnings of mitochondrial transfer, Werner’s team identified the protein MIRO2 as a key facilitator in this process. MIRO2, known for its role in mitochondrial trafficking within neurons, is highly expressed in cancer cells actively transferring mitochondria. Its presence was particularly concentrated at the invasive fronts of tumors, precisely where cancer cells interact most intimately with the surrounding stroma, including fibroblasts.

Using clinical tissue samples, researchers localized MIRO2 expression to tumor cells at the margins infiltrating connective tissue, corroborating its functional significance in vivo. This localization suggests that MIRO2-mediated mitochondrial transfer is a critical mechanism that tumors leverage during invasion and metastasis. Importantly, inhibiting MIRO2 expression or function effectively blocked mitochondrial transfer in both laboratory cell cultures and preclinical mouse models, preventing fibroblast reprogramming and dampening tumor-supportive activities.

These findings open promising avenues for therapeutic intervention. Targeting MIRO2 to disrupt mitochondrial transfer could impair the tumor’s ability to reprogram its microenvironment, thereby stalling progression and metastasis. However, the transition from laboratory models to human applications remains a formidable challenge. Potential MIRO2 inhibitors will require rigorous development to ensure specificity, minimal side effects, and clinical efficacy.

While the timeline for clinical translation remains uncertain, this discovery sets the stage for innovative cancer treatments centered around disrupting the metabolic and cellular dialogue between tumor cells and their stroma. Through such interventions, it may become possible to curtail tumor growth by dismantling the support systems that cancer cells covertly establish within their microenvironment.

As cancer research advances, understanding and intercepting intercellular interactions such as mitochondrial transfer will be critical for developing next-generation therapies. The ETH Zurich team’s work is a testament to how fundamental cellular mechanisms, once uncovered, can reveal hidden vulnerabilities in the seemingly invincible nature of malignant tumors.

Subject of Research:
Mitochondrial transfer from cancer cells to fibroblasts and its role in tumor progression.

Article Title:
MIRO2-mediated mitochondrial transfer from cancer cells induces cancer-associated fibroblast differentiation.

News Publication Date:
28-August-2025

Web References:
https://doi.org/10.1038/s43018-025-01038-6

References:
Cangkrama M, Liu H, Wu X, et al. MIRO2-mediated mitochondrial transfer from cancer cells induces cancer-associated fibroblast differentiation. Nature Cancer. 28 August 2025. DOI: 10.1038/s43018-025-01038-6

Image Credits:
Michael Cangkrama / ETH Zurich / BioRender

Keywords:
Mitochondrial transfer, cancer-associated fibroblasts, tumor microenvironment, MIRO2 protein, skin cancer, intercellular communication, extracellular matrix remodeling, tumor progression, mitochondrial trafficking, stromal reprogramming, therapeutic targeting, cancer metabolism

Human prostate cancer samples exhibiting perineural invasion—a condition where cancer cells encroach upon or surround nerves—displayed a significantly elevated mitochondrial load within cancer cells proximal to nerves. Using high-throughput multispectral imaging coupled with machine learning algorithms, researchers quantified mitochondrial abundance across tens of thousands of cells. Their precise spatial analysis revealed that cancer cells neighboring nerves harbored considerably more mitochondria than their distant counterparts, suggesting a nerve-dependent metabolic advantage in these cancer cells.

To further dissect whether this phenomenon involved actual mitochondrial transfer rather than mere mitochondrial biogenesis within cancer cells, the research team leveraged a clinical trial involving chemical denervation of the human prostate using botulinum neurotoxin A (BoNT/A). This intervention selectively reduced neuronal activity at the tumor site, serving as a natural experiment to observe the influence of neuronal innervation on cancer mitochondrial content. Remarkably, cancer cells on the denervated side exhibited a stark reduction in mitochondrial load, directly linking neuronal presence to mitochondrial enrichment in tumor cells and strongly implying transfer of mitochondria from nerves to cancer.

To substantiate these findings with robust in vivo models, the researchers employed a BALB/c mouse xenograft system, where murine dorsal root ganglion (DRG) neurons innervating the mammary fat pad were genetically modified to express a mitochondria-targeted green fluorescent protein (GFP) reporter under the synapsin-1 promoter, allowing for neuron-specific mitochondrial labeling. Following the injection of 4T1 breast cancer cells tagged with a red fluorescent protein (mCherry) into the same fat pad, analysis of emerging tumors by flow cytometry detected a distinct subpopulation of cancer cells emitting the GFP mitochondrial signal. This provided compelling evidence that mouse host neurons transferred mitochondria directly into malignant cells within the tumor microenvironment.

Notably, this transfer was shown to be specific to mitochondria, as a control lentiviral construct encoding a nucleus-localized GFP failed to show any signal exchange, ruling out nonspecific protein transfer or artifact. This elegant genetic design confirmed that intact mitochondria, rather than soluble proteins or other organelles, crossed from host neurons into cancer cells in situ, emphasizing the precision and selectivity of this intercellular communication.

Beyond imaging and fluorescence-based assays, the team implemented advanced genetic approaches to detect mitochondrial DNA (mtDNA) transfer at the molecular level. By identifying distinct mtDNA polymorphisms inherent to the host mouse strain and the transplanted cancer cells through Sanger sequencing, they established a unique molecular signature. Cancer cells recovered from tumors via fluorescence-activated cell sorting (FACS) underwent deep Oxford Nanopore sequencing to detect the presence of host-derived mtDNA within the tumor cell population. The results definitively demonstrated heteroplasmy—cancer cells contained a mixture of their own and neuron-derived mtDNA—validating that mitochondrial transfer is not merely a superficial event but involves functional genetic material.

Importantly, denervation via BoNT/A treatment in the xenograft model resulted in a significant decrease of approximately 35% in the mitochondrial transfer events from neurons to cancer cells. This implies that neural activity and integrity are key drivers of mitochondrial donation, and that interfering with nerve presence or function may modulate tumor metabolism and progression by denying cancer cells this mitochondrial influx.

The implications of nerve-to-cancer mitochondrial transfer are profound, as mitochondria are central to energy production, metabolic adaptation, and apoptotic regulation. Mitochondrial acquisition by cancer cells could endow them with enhanced bioenergetic capacity, resistance to metabolic stress, and even influence metastatic potential. This discovery adds a new dimension to tumor–nerve interactions, previously focused largely on growth factor secretion and neurotransmitter release, by highlighting organelle-level communication.

From a therapeutic standpoint, these findings suggest new intervention points. Chemical denervation or strategies to block mitochondrial transfer mechanisms may disrupt this symbiotic relationship, potentially depriving cancer cells of vital metabolic support and hindering tumor growth and metastasis. Furthermore, the use of neuron-specific mitochondrial reporters in preclinical models paves the way for real-time imaging and therapeutic monitoring in future studies.

The researchers’ methodical approach, combining clinical patient sample analysis, advanced imaging platforms, genetic manipulation, and rigorous sequencing, exemplifies the power of multidisciplinary strategies in unraveling complex cellular communications. Their use of machine learning for image quantification allowed unprecedented cellular resolution and statistical power to detect subtle spatial mitochondrial variations linked to nervous system presence.

As cancer research continues to unravel the tumor microenvironment’s multifaceted influencers, the role of nerves emerges as a critical, active participant rather than a mere passive structure. The revelation that neurons can donate mitochondria to cancer cells during metastasis challenges classical tumor biology and invites new perspectives on tumor–neuron crosstalk.

Future research will need to clarify the precise molecular machinery mediating mitochondrial transfer, such as tunneling nanotubes, extracellular vesicles, or synaptic-like junctions, and how these processes are regulated by the tumor microenvironment. Understanding the downstream metabolic and signaling consequences of mitochondrial acquisition on cancer cell behavior will be equally critical.

In sum, this pioneering study illuminates a novel biological axis in cancer metastasis—the nerve-to-cancer mitochondrial conduit—adding an organelle-centric lens to investigate tumor progression and offering novel targets for therapeutic innovation. As interdisciplinary efforts converge, exploiting neural physiology to impede cancer’s metabolic support systems may forge new frontiers in oncology.

Subject of Research: Mitochondrial transfer from nerves to cancer cells during cancer metastasis

Article Title: Nerve-to-cancer transfer of mitochondria during cancer metastasis

Article References:
Hoover, G., Gilbert, S., Curley, O. et al. Nerve-to-cancer transfer of mitochondria during cancer metastasis. Nature (2025). https://doi.org/10.1038/s41586-025-09176-8